New biomarkers in SLE: from bench to bedside

Area of Science:

• Immunology
• Nephrology
• Rheumatology

Background:

• Biomarkers are crucial for diagnosing, monitoring, and predicting treatment response in Systemic Lupus Erythematosus (SLE).
• Established biomarkers are vital, but new markers are continuously being investigated for improved patient management.

Purpose of the Study:

• To review recently proposed serum and urinary biomarkers for SLE diagnosis and management.
• To discuss the potential of novel biomarkers in understanding SLE pathogenesis and guiding therapy.

Main Methods:

• Review of recent scientific literature on novel biomarkers for SLE.
• Evaluation of assays for complement proteins, chemokines, lectins, and cytokines (e.g., BAFF).
• Analysis of proposed urinary biomarkers related to kidney inflammation and cell survival in SLE.

Main Results:

• Novel assays for complement proteins offer improved evaluation of these established SLE biomarkers.
• Chemokines and lectins show promise as biomarkers for the interferon (IFN) signature in SLE.
• BAFF family cytokines are linked to B cell perturbations, a key mechanism in SLE pathogenesis.
• Numerous urinary biomarkers are proposed, reflecting kidney-specific inflammation and cell damage in SLE.

Conclusions:

• Novel serum and urine biomarkers offer new avenues for SLE diagnosis and monitoring.
• Combining traditional and novel biomarkers may provide the most effective strategy for classifying, staging, and treating SLE patients.